SCIENCE-TECHNOLOGY-ENVIRONMENT-HEALTH

Deepverge is a vertically integrated business, collaborating technology platforms with partners in AI, clinical research, medical

device, life science and environmental science.

York UK, Cork/Dublin Ireland, Poland, Delaware USA, Shanghai China.

INTERIM REPORT PRESENTATION SEPT 2021

Interim 2021 Highlights• H1 2020 revenue £3.319m is an increase of 230% from H1 2020 (£1.004m);

• EBITDA (loss) before exceptional items £0.697m (H1 2020: £0.552m);

• Administration costs increased to £4.211m (2019: £1.547m) with large increase in

staff (74) across all divisions and the incorporation of Modern Water business;

• Operating loss of £2.311m (H1 2020: £0.936m) after providing for:

o Depreciation of £0.193m (H1 2020: £0.072m);

o Amortisation of £1.360m (2020: £0.312m) (increase due to higher

intangibles from acquisitions);

o Exceptional costs of £0.061m (2020: £nil);

• Net Assets at 30 June 2021 £25.3m (2020: £4.3m)

• £10m Placing and Subscription completed in June 2021 at 30 pence.

• Finance available to the Group at period end in excess of £9m:

o Cash and cash equivalents of £7.59m

o Finance availability of £1.50m

Laboratory Capacity - 20,000 per month – Main Promotional Launch Q4

Media Monks appointed agency partner

Media Monks (part of S4 Capital – www.s4capital.com) have been selected

as our partner to launch Skin Trust Club as a brand, and drive subscriptions

to 20,000 in the UK & Irish market initially

Their global reach allows for easy launches in subsequent markets

Campaign includes the following:

● A clear, integrated launch strategy

● Influencer led campaign identifying specific target audiences

● Media & campaign distribution and management

● Campaign monitoring and reporting

● Data collecting - informing future optimisation strategies

Microtox®PD Wastewater

Full turnkey design solution of pre-production evaluation batch builds and full designs for mass production capability.

1. Hardware design capable of mass manufacture 2. Multiplex Chip design to identify additional pathogens for mass production3. IT/software/systems to handle data volumes for mass surveillance

➔ AI training to identify additional pathogens➔ Software/data integration and security for collection and sharing at a mass

surveillance level

Delivering real and near-time data on wastewater state from sensors to stakeholders in a usable, understandable and contextually aware fashion, while also unlocking millions of completely new data points to unearth new and better ways to manage water issues.

Microtox® BT Breath TestMultiplex Chip To Identify More Pathogen Targets Development and design for a mass-producible photonic biosensor based on success of current technology:

➔ New iterative fabrication to allow optimised versions of the grating design.

➔ Chips being developed to cover four iterations with at least two further pathogen bindings - possibly Norovirus and PPMoV.

➔ Existing pathogen bindings have been shown to be able to capture / detect cancerous cells

11

FINANCIAL RESULT £’000 H1-21 H1-20 FY-20 FY-20

TurnoverCost of Sales

Gross Profit

Administrative Costs

Operating Gains

EBITDA Loss (adjusted)

Operating LossTotal Comprehensive Loss

---------------------------

Net Assets

Cash & Cash Equivalents

3,319(1,581)

1,738

(4,211)

162

(697)

(2,311)(2,669)

--

25.3m

7.59m

1,004

(393)

611

(1,547)

-

(552)(936)

(858)

--

4.3m0.25m

4,483(2,639)

1,844

(4,561)

-

(859)

(2,717)(2,685)

--

15.9m

1.44m

231%302%

184%

172%

26%

146%210%

--

488%

2,876%

Financial Highlights Movement

Admin costs increased due to Modern Water

acquisition, Labskin & Skin Trust Club

expansion

Staff Numbers

June 2020 – 30June 2021 – 57Sept 2021 – 74

12

Statement of Financial PositionFINANCIAL RESULT £’000 H1-21 H1-20 FY-20

Intangible Assets 18,959 3,512 18,241PPE 988 483 874Right of use assets 1,705 450 569Other 354 708 354Non Current Assets 22,006 5,154 20,038Inventories 1,953 79 1,347Trade and Receivables 2,219 1,079 1,448Cash & cash equivalents 7,589 255 1,441Current Assets 11,761 1,413 4,236Total Assets 33,767 6,507 24,274Trade and Other Payables 2,232 970 2,667Lease Liabilities 446 105 264Deferred Tax 356 61 328Borrowings 1,125 154 1,349Total Current Liabilities 4,159 1,290 4,608Deferred Tax 2,870 470 2,780Deferred revenue/government grants 21 6 24Lease liabilities 1,334 355 358Borrowings 83 121 583Total Non Current Liabilities 4,308 952 3,745Share Capital and Premium 39,411 14,160 27,449Retained Loss (20,609) (16,325) (18,964)Other Reserves 6,498 6,490 6,647Non-Controlling Interests 0 0 789Total Equity 25,300 4,325 15,921

Total Equity and non current liabilities 33,767 6,567 (370)

Intangible Assets – Acquisitions2020/21 Modern Water £13.30m2019 Rinocloud £ 3.00m

Current Assets IncreaseMW Microtox and Reagent stocksInventories £1.95mCash Balance £7.58mFacility Credit £1.50m

Liabilities – BorrowingsMezz Finance £1.13mShort term loans £0.10m

Share Capital – Movement in H1 2021Warrants/Options £1.32mShare Placing 11 June £6.33mShare Placing 25 June £3.67m

Outlook – What’s Coming Up

➔ Skin Trust Club - Capacity of 20,000 Home Test Kits per month with Android and availability in multiple countries by end of this year

➔ Wastewater – Proven Microtox PD installed. New installations to be announced before the end of this year in multiple jurisdictions

➔ Breath Test - Microtox BT tests ongoing. To become part of a multi-industry solution for COVID19. The virus is here to stay.

➔ China Resources - negotiations are ongoing. Due to production demand & Phase III results expected early 4th quarter.

➔ ION Exchange (India) Ltd – Centre of Excellence for India and Middle East and multiple AMBC Zero Liquid Discharge installations in 2022.

➔ Labskin – Clients continue to grow with Tier One global consumer skin, health and pharma corporations (multiple six-figure value deals)

➔ Expansion - Laboratories in UK, US and Ireland meeting increased demand for human, environmental health with AI and data analytics

➔ Multiplex chip trials - First real-time pathogen/virus surveillance to include multiple pathogens on one microchip